Home・Список акций・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Закрыт

3.98 2.05

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.71

Макс.

4.11

Ключевые показатели
By Trading Economics
Доход	-42M -78M
Прибыль на акцию	-0.59
Сотрудники	106
EBITDA	-42M -77M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+114.84% upside

Дивиденды
By Acuity
Следующий отчет о доходах	6 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	25M 356M
Предыдущая цена открытия	1.93
Предыдущая цена закрытия	3.98

Zentalis Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 сент. 2026 г., 23:56 UTC

C.H. Robinson Worldwide shares are lower in after-market trading, despite a broader market rally amid reduced interest rate hike expectations.

3 сент. 2026 г., 23:56 UTC

News

Missouri American Water acquired Neosho's water systems for $34.5 million, adding 5,400 customers. Shares of American Water Works traded higher in after-market hours.

3 сент. 2026 г., 23:56 UTC

SiTime Corp shares are lower in after-market hours, continuing a decline that began earlier, despite gains in major indices.

3 сент. 2026 г., 23:56 UTC

Elme Communities shares traded roughly flat in after-market hours. Broader market trends reflect gains in major averages amid reduced interest rate hike expectations.

3 сент. 2026 г., 23:56 UTC

News

Correlated Moves

Paychex receives a buy rating on strong revenue growth and strategic AI integration. After-market trading has shown little change since Thursday's close.

3 сент. 2026 г., 23:56 UTC

News

Jefferies initiated coverage on Nexgen Energy with a Buy rating and a C$21 price target. Shares moved higher in after-market hours.

3 сент. 2026 г., 23:56 UTC

Tapestry Inc. shares rose slightly in after-market trading, reflecting broader market gains amid reduced interest rate hike expectations. They remain below their 20-day moving average.

3 сент. 2026 г., 23:56 UTC

Loews Corp shares are higher in after-market hours, reflecting broader market gains amid reduced interest rate hike expectations.

3 сент. 2026 г., 23:56 UTC

Union Pacific Corp shares are higher in after-market trading, following gains in major indices amid reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

3 сент. 2026 г., 23:56 UTC

Sportsman's Warehouse shares advanced in after-market trading, reflecting broader market gains amid reduced expectations for an interest rate hike.

3 сент. 2026 г., 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-hours trading, continuing a decline since Thursday's close, despite broader market gains. No specific news was identified.

3 сент. 2026 г., 23:56 UTC

General Motors traded roughly flat after-market hours amid strong market momentum driven by reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

3 сент. 2026 г., 23:56 UTC

Wingstop Inc shares are trading higher in after-market hours, supported by strong gains in major indices amid reduced interest rate hike expectations, according to CME Group.

3 сент. 2026 г., 23:51 UTC

Exelon Corp shares are lower in after-market hours, diverging from broader market gains amid anticipation of upcoming employment data. No specific news was identified.

3 сент. 2026 г., 23:51 UTC

Japan's Household Spending Falls 3.6% YoY in July, Marking Eighth Straight Month of Decline Amid Economic Uncertainty

3 сент. 2026 г., 23:51 UTC

Japan's Household Spending MoM for July rises 0.5%, falling short of 2.6% expectations, raising concerns over consumer behavior amid a year-on-year decline of 3.6%.

3 сент. 2026 г., 23:51 UTC

Canada's Ivey PMI forecasted to rise to 56.2 in August, signaling cautious optimism amid mixed business confidence trends and regional recovery signals.

3 сент. 2026 г., 23:51 UTC

Iovance Biotherapeutics Inc shares are higher in after-market trading, maintaining a position above its 20-day moving average amid broader market gains.

3 сент. 2026 г., 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

3 сент. 2026 г., 23:51 UTC

News

Social Media

Dutch Bros Inc filed a mixed securities shelf registration, enabling potential issuance of various securities. Shares are trading higher in after-market hours.

3 сент. 2026 г., 23:51 UTC

Yelp Inc shares are higher in after-market trading, following gains in the broader market. No specific company news was identified to explain the movement.

3 сент. 2026 г., 23:51 UTC

News

Social Media

Tesla Inc. shares are lower in after-market trading following the invite-only launch event for its Cybercab in Austin, as details remain restricted.

3 сент. 2026 г., 23:51 UTC

Shake Shack Inc shares are lower in after-market hours, continuing a downward trend below the 20-day moving average and nearing the one-month range low.

3 сент. 2026 г., 23:46 UTC

Hilton Worldwide Holdings Inc shares are trading higher in after-market hours, supported by gains in major indices amid anticipation of Friday's employment report.

3 сент. 2026 г., 23:46 UTC

Correlated Moves

Kimco Realty Corp shares are lower in after-market hours, reflecting a decline since Thursday's close. Broader market trends also show weakness.

3 сент. 2026 г., 23:46 UTC

News

Weyerhaeuser Co remains about 4.95% below its 20-day moving average. Shares were roughly flat in after-market hours following a price target cut to $28.

3 сент. 2026 г., 23:46 UTC

FedEx Corp shares are lower in after-market trading, reflecting a decline from Thursday's close. The stock showed initial strength before pulling back.

3 сент. 2026 г., 23:46 UTC

Correlated Moves

AMETEK Inc. shares declined in after-market trading, reflecting broader small-cap market trends amid significant gains in major indices earlier in the session.

3 сент. 2026 г., 23:46 UTC

Correlated Moves

Box Inc shares are lower in after-market hours following significant volatility. The decline may be linked to a drop in Asana Inc's stock.

3 сент. 2026 г., 23:46 UTC

Marcus & Millichap shares are lower in after-market trading, despite broader market gains. No specific news was identified to explain the decline.

Сравнение c конкурентами

Изменение цены

Zentalis Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

114.84% рост

Прогноз на 12 месяцев

Средняя 8.83 USD 114.84%

Максимум 11 USD

Минимум 5 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Zentalis Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

Покупка

Удержание

Продажа

Основано на мнении 6 аналитиков, присваивавших рейтинги акциям Zentalis Pharmaceuticals Inc – Данные за последние 3 месяца.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.